Navigation Links
Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
Date:5/8/2012

acetylcholine and histamine in specific areas of the brain.

About depression

Depression is a very common, debilitating illness affecting around 121 million people worldwide, according to the World Health Organization (WHO).  Depression was the leading cause of disability and the fourth leading contributor to the global burden of disease in 2000.  According to the National Alliance on Mental Illness (NAMI), depression affects more than 6.5 million of the 35 million Americans aged 65 years or older.

The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically. Symptoms can include feelings of sadness, anxiety, loss of interest in activities, decreased energy, impaired sleep, impaired concentration or indecisiveness, hopelessness, guilt, persistent physical symptoms such as pain and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts.

Takeda and Lundbeck alliance

In September 2007, Lundbeck and Takeda formed a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeck's pipeline for the treatment of mood and anxiety disorders. The partnership initially focuses on co-development and co-commercialization of the two most advanced compounds in Lundbeck's pipeline for mood and anxiety disorders, Lu AA21004 and Lu AA24530. If approved, the companies will co-promote the products in the United States and Japan.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epileps
'/>"/>

SOURCE H. Lundbeck A/S; Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... CINCINNATI, July 7 Procter & Gamble Pharmaceuticals (P&GP) ... tablets, which are indicated for the treatment of moderately ... disease. UC involves inflammation of the lining of the ... followed by periods of remission. Moderately active UC is ...
... Tenn., July 6 /PRNewswire/ -- A Pebble Beach ... cure for multiple sclerosis. The researchers took home the top ... and the non-profit Band Against MS (BAMS) organization. The money ... at the University of Texas Health Science Center at ...
Cached Medicine Technology:Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 2Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 3Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 4Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 5Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research 2
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... September 01, 2014 Registration is now open ... 5K and 1-Mile Race to be held on Sunday, September ... Court Yard at Harmon Meadow in Secaucus, New Jersey. All ... a national nonprofit dedicated to restoring a sense of self, ... members and our military families. , General registration is $30 ...
(Date:9/1/2014)... The Outlier Series announced the next short ... from one of the exceptional women featured in the ... Changers . The title of the upcoming mini e-Book ... McClendon . McClendon is currently a full-time physician’s assistant, ... of WeTV show, Raising Sextuplets. , Jenny was chosen ...
(Date:9/1/2014)... 2014 Beginning Tuesday, September 2nd, Las ... professionals and 10,000 consumers for the annual gathering known ... of the nation’s top medical professionals who specializes in ... The week-long event contains more than 120 hours of ... in the pain management field. , MarijuanaDoctors.com is pleased ...
(Date:8/31/2014)... 31, 2014 MYMOBILEUNI (MMU) strategy ... social media marketing tools access to digital, resources, ... will utilize all tools to reach and collaborate ... our multiple learning channels. , MMU, today announced ... an authoring tool that applies social networking concepts ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3
... have some beneficial effects in fighting cancer, new research ... potential to perform better with this ingredient//. ,Vaccines work ... tissues and destroy them. But often, the immune system ... the healthy ones. ,But researchers at University ...
... Court would pass judgment regarding an appeal by health officials, ... a 17-month-old boy die//. Lawyers who are currently handling the ... of life is so poor and that doctors should be ... the boy and the treating physicians have not been revealed ...
... researchers said that mammograms were able to detect non ... Some previous studies// show that 54% of the mammograms ... rate is about 1% only. But the present study ... ,Dr. Sophia Zackrisson, a radiologist from the Epidemiological Research ...
... Center have zoned in on new molecular indicators, called ... be an interesting pointer when evaluating anti-aging therapies. The ... latest issue of the Journal of Investigative Dermatology. ... and cosmetic industries in developing products that will minimize ...
... who use the Internet more frequently are found to ... and social lives. Studies also suggested// that there is ... ,The Rotterdam-based Institute for Research into Lifestyles and Addiction ... 15 and found that what it termed "compulsive internet ...
... recent mental health study conducted by Dr. Michelle Hindin ... their parents are at an increased risk// of developing ... the respondents reported witnessing parental domestic violence. ... 5 female adolescents wished that they had died in ...
Cached Medicine News:Health News:Life Or Death: Parents Await High Court Judgment 2Health News:Mammograms Detect Non Progressive Cancer 2Health News:Biomarkers Could Prove Significant In Understanding Aging Process 2
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: